Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
70.36
-0.78 (-1.10%)
Streaming Delayed Price
Updated: 11:05 AM EST, Dec 7, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
776,903
Open
70.74
Bid (Size)
70.30 (2)
Ask (Size)
70.41 (2)
Prev. Close
71.14
Today's Range
69.09 - 71.00
52wk Range
37.55 - 76.19
Shares Outstanding
78,935,098
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
Today 5:30 EST
Shareholders will do well to prepare themselves for how regulators might react.
Via
The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
Today 5:21 EST
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.
Via
The Motley Fool
Performance
YTD
+71.60%
+71.60%
1 Month
+36.40%
+36.40%
3 Month
+37.71%
+37.71%
6 Month
+12.07%
+12.07%
1 Year
+38.55%
+38.55%
More News
Read More
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Today 5:15 EST
Via
InvestorPlace
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
December 06, 2023
Via
The Motley Fool
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
December 06, 2023
Via
Benzinga
The Latest Analyst Ratings for CRISPR Therapeutics
December 05, 2023
Via
Benzinga
Is CRISPR Therapeutics the Best Gene-Editing Stock?
November 22, 2023
Via
The Motley Fool
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases
December 05, 2023
Via
Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
December 05, 2023
Via
The Motley Fool
The Market's Up This Year. Do You Feel Like You Are Winning?
December 04, 2023
Via
The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
Via
The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
December 04, 2023
Via
The Motley Fool
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
December 04, 2023
Via
The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
December 03, 2023
Via
The Motley Fool
An Important History Lesson for Gene-Editing Investors
December 02, 2023
Via
The Motley Fool
5 Top Stocks to Buy Before 2024
December 02, 2023
Via
The Motley Fool
Five Best Performing Stocks Of The Top ETF Of November
December 01, 2023
Via
Talk Markets
Topics
ETFs
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
December 01, 2023
Via
The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
December 01, 2023
Via
The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
November 30, 2023
Via
InvestorPlace
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
November 29, 2023
Via
Benzinga
Topics
ETFs
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback'
November 29, 2023
Via
Benzinga
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
November 28, 2023
Via
InvestorPlace
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
November 28, 2023
Via
The Motley Fool
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
November 25, 2023
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.